Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert I. Haddad, Marshall R. Posner, Anne O’Neill et al.|The Lancet Oncology|2013Cited by 748
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trialMarshall R. Posner, Kevin J. Cullen, Jochen H. Lorch et al.|Annals of Oncology|2011Cited by 487
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trialJochen H. Lorch, Marshall R. Posner, Olga Goloubeva et al.|The Lancet Oncology|2011Cited by 447
Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer PatientsKathleen Settle, Kevin J. Cullen, Marshall R. Posner et al.|Cancer Prevention Research|2009Cited by 297
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al.|Haematologica|2015Cited by 252